Published in Cancer Res on February 23, 2010
The emergence of lncRNAs in cancer biology. Cancer Discov (2011) 6.32
lncRNAdb: a reference database for long noncoding RNAs. Nucleic Acids Res (2010) 4.49
microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene (2011) 3.02
MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol (2012) 2.41
Long non-coding RNA: a new player in cancer. J Hematol Oncol (2013) 2.26
Concern The functional role of long non-coding RNAs and epigenetics. Biol Proced Online (2014) 1.73
Long Noncoding RNAs in Cancer Pathways. Cancer Cell (2016) 1.63
Long non-coding RNA in cancer. Int J Mol Sci (2013) 1.52
Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. Am J Transl Res (2012) 1.33
Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets. Mol Cell Ther (2015) 1.32
Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression. J Exp Clin Cancer Res (2015) 1.29
Long noncoding RNA involvement in cancer. BMB Rep (2012) 1.28
Long noncoding RNA HOTAIR is associated with motility, invasion, and metastatic potential of metastatic melanoma. Biomed Res Int (2013) 1.21
Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6. PLoS One (2013) 1.19
Long noncoding RNAs: a potential novel class of cancer biomarkers. Front Genet (2015) 1.17
Role of the lncRNA-p53 regulatory network in cancer. J Mol Cell Biol (2014) 1.16
Long noncoding RNAs-related diseases, cancers, and drugs. ScientificWorldJournal (2013) 1.07
The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma. PLoS One (2015) 1.07
Long noncoding RNAs in cancer: from function to translation. Trends Cancer (2015) 1.06
Long non-coding RNAs and complex human diseases. Int J Mol Sci (2013) 1.03
Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas. Am J Pathol (2011) 1.01
Epigenetics: an emerging player in gastric cancer. World J Gastroenterol (2014) 1.01
The bright side of dark matter: lncRNAs in cancer. J Clin Invest (2016) 0.94
Analysis of gene expression profiling in meningioma: deregulated signaling pathways associated with meningioma and EGFL6 overexpression in benign meningioma tissue and serum. PLoS One (2012) 0.94
Long noncoding RNA plays a key role in metastasis and prognosis of hepatocellular carcinoma. Biomed Res Int (2014) 0.94
Genetic/molecular alterations of meningiomas and the signaling pathways targeted. Oncotarget (2015) 0.93
Regulatory Roles for Long ncRNA and mRNA. Cancers (Basel) (2013) 0.92
Noncoding RNAs involved in mammary gland development and tumorigenesis: there's a long way to go. J Mammary Gland Biol Neoplasia (2012) 0.92
Noncoding RNAs in cancer and cancer stem cells. Chin J Cancer (2013) 0.92
Knockdown of a novel lincRNA AATBC suppresses proliferation and induces apoptosis in bladder cancer. Oncotarget (2015) 0.90
Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma. Oncotarget (2016) 0.88
Small nucleolar RNA 113-1 suppresses tumorigenesis in hepatocellular carcinoma. Mol Cancer (2014) 0.86
Ectopic expressed long non-coding RNA H19 contributes to malignant cell behavior of ovarian cancer. Int J Clin Exp Pathol (2015) 0.86
Decreased expression of long non-coding RNA GAS5 indicates a poor prognosis and promotes cell proliferation and invasion in hepatocellular carcinoma by regulating vimentin. Mol Med Rep (2015) 0.86
Construction and analysis of lncRNA-lncRNA synergistic networks to reveal clinically relevant lncRNAs in cancer. Oncotarget (2015) 0.83
Long non-coding RNAs and p53 regulation. Int J Mol Sci (2012) 0.83
Long non-coding RNAs in haematological malignancies. Int J Mol Sci (2013) 0.83
Epigenetic silencing of monoallelically methylated miRNA loci in precancerous colorectal lesions. Oncogenesis (2013) 0.83
Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs. Neuro Oncol (2015) 0.82
High expression of long non-coding RNA lncRNA-ATB is correlated with metastases and promotes cell migration and invasion in renal cell carcinoma. Jpn J Clin Oncol (2016) 0.82
Loss of non-coding RNA expression from the DLK1-DIO3 imprinted locus correlates with reduced neural differentiation potential in human embryonic stem cell lines. Stem Cell Res Ther (2015) 0.82
Long noncoding RNAs during normal and malignant hematopoiesis. Int J Hematol (2014) 0.82
Evolutionary conservation and functional roles of ncRNA. Front Genet (2012) 0.81
Long non-coding RNAs in normal and malignant hematopoiesis. Oncotarget (2016) 0.81
A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma. Oncotarget (2017) 0.81
Neighborhood and Family Environment of Expectant Mothers May Influence Prenatal Programming of Adult Cancer Risk: Discussion and an Illustrative DNA Methylation Example. Biodemography Soc Biol (2016) 0.80
Knockdown of linc-POU3F3 suppresses the proliferation, apoptosis, and migration resistance of colorectal cancer. Oncotarget (2016) 0.79
CCAT1: an oncogenic long noncoding RNA in human cancers. J Cancer Res Clin Oncol (2016) 0.79
MEG3 long noncoding RNA contributes to the epigenetic regulation of epithelial-mesenchymal transition in lung cancer cell lines. J Biol Chem (2016) 0.78
Expression of the lncRNA Maternally Expressed Gene 3 (MEG3) Contributes to the Control of Lung Cancer Cell Proliferation by the Rb Pathway. PLoS One (2016) 0.78
Long noncoding RNA variations in cardiometabolic diseases. J Hum Genet (2016) 0.77
Long Noncoding RNA MEG3 Interacts with p53 Protein and Regulates Partial p53 Target Genes in Hepatoma Cells. PLoS One (2015) 0.77
Regulatory non-coding RNA: new instruments in the orchestration of cell death. Cell Death Dis (2016) 0.77
A genomic screen for long noncoding RNA genes epigenetically silenced by aberrant DNA methylation in colorectal cancer. Sci Rep (2016) 0.77
LncRNA16 is a potential biomarker for diagnosis of early-stage lung cancer that promotes cell proliferation by regulating the cell cycle. Oncotarget (2017) 0.76
Downregulation of the Long Non-Coding RNA Meg3 Promotes Angiogenesis After Ischemic Brain Injury by Activating Notch Signaling. Mol Neurobiol (2016) 0.76
Regulation of Mammalian Gene Dosage by Long Noncoding RNAs. Biomolecules (2013) 0.76
Long Noncoding RNA CCAT2 as a Potential Novel Biomarker to Predict the Clinical Outcome of Cancer Patients: A Meta-Analysis. J Cancer (2017) 0.76
Plasma LncRNA-ATB, a Potential Biomarker for Diagnosis of Patients with Coal Workers' Pneumoconiosis: A Case-Control Study. Int J Mol Sci (2016) 0.75
Knockdown of linc-UFC1 suppresses proliferation and induces apoptosis of colorectal cancer. Cell Death Dis (2016) 0.75
Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations. Cancer Discov (2016) 0.75
Brain tumors: Special characters for research and banking. Adv Biomed Res (2015) 0.75
Long non-coding RNA GAS5 inhibits cell proliferation, induces G0/G1 arrest and apoptosis, and functions as a prognostic marker in colorectal cancer. Oncol Lett (2017) 0.75
High expression of the long non-coding RNA HEIRCC promotes Renal Cell Carcinoma metastasis by inducing epithelial-mesenchymal transition. Oncotarget (2016) 0.75
microRNA-22 can regulate expression of the long non-coding RNA MEG3 in acute myeloid leukemia. Oncotarget (2017) 0.75
Role of long non-coding RNAs in glucose metabolism in cancer. Mol Cancer (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
p53 and human cancer: the first ten thousand mutations. Adv Cancer Res (2000) 4.71
Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell (1993) 4.19
A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell (1998) 3.89
Activation of p53 by MEG3 non-coding RNA. J Biol Chem (2007) 3.07
Novel imprinted DLK1/GTL2 domain on human chromosome 14 contains motifs that mimic those implicated in IGF2/H19 regulation. Genome Res (2000) 2.73
The Dlk1 and Gtl2 genes are linked and reciprocally imprinted. Genes Dev (2000) 2.68
A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab (2003) 2.68
Epigenetic analysis of the Dlk1-Gtl2 imprinted domain on mouse chromosome 12: implications for imprinting control from comparison with Igf2-H19. Hum Mol Genet (2002) 2.33
Inhibition of adipogenesis and development of glucose intolerance by soluble preadipocyte factor-1 (Pref-1). J Clin Invest (2003) 2.21
Delta-like and gtl2 are reciprocally expressed, differentially methylated linked imprinted genes on mouse chromosome 12. Curr Biol (2000) 2.19
Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. Genes Cells (2000) 1.90
Regulation of human skeletal stem cells differentiation by Dlk1/Pref-1. J Bone Miner Res (2004) 1.79
Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A (1997) 1.76
The mouse Gtl2 gene is differentially expressed during embryonic development, encodes multiple alternatively spliced transcripts, and may act as an RNA. Dev Dyn (1998) 1.74
The callipyge mutation enhances the expression of coregulated imprinted genes in cis without affecting their imprinting status. Nat Genet (2001) 1.71
Molecular genetic approach to human meningioma: loss of genes on chromosome 22. Proc Natl Acad Sci U S A (1987) 1.63
Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev (2002) 1.43
The role of the epidermal growth factor-like protein dlk in cell differentiation. Histol Histopathol (2000) 1.42
Comparative sequence analysis of the imprinted Dlk1-Gtl2 locus in three mammalian species reveals highly conserved genomic elements and refines comparison with the Igf2-H19 region. Genome Res (2001) 1.41
Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. Br J Cancer (2005) 1.39
Gtl2lacZ, an insertional mutation on mouse chromosome 12 with parental origin-dependent phenotype. Mamm Genome (1996) 1.34
Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J Clin Endocrinol Metab (2005) 1.34
Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab (2008) 1.33
Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res (1995) 1.33
Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma. Proc Natl Acad Sci U S A (1987) 1.30
Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer (2007) 1.30
Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab (2002) 1.29
NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene (1999) 1.21
Meningioma: an update. Curr Opin Neurol (2004) 1.16
DNA damage-induced inhibition of securin expression is mediated by p53. J Biol Chem (2002) 1.16
DLK1: increased expression in gliomas and associated with oncogenic activities. Oncogene (2006) 1.15
Cytological and cytogenetical studies on human meningioma. Cancer Genet Cytogenet (1982) 1.14
Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry (2004) 1.13
Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma. Hum Mol Genet (2006) 1.07
Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas. Oncogene (2003) 1.06
Inactivation of imprinted genes induced by cellular stress and tumorigenesis. Cancer Res (2005) 1.04
Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J Neurosurg (1999) 0.99
Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol (2001) 0.97
Incidence of numerical chromosome aberrations in meningioma tumors as revealed by fluorescence in situ hybridization using 10 chromosome-specific probes. Cytometry (2002) 0.94
Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus. Oncogene (1997) 0.93
Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation. Mod Pathol (2004) 0.91
Expression, biosynthesis and release of preadipocyte factor-1/ delta-like protein/fetal antigen-1 in pancreatic beta-cells: possible physiological implications. J Endocrinol (2003) 0.91
Loss of heterozygosity of chromosome 14q in low- and high-grade meningiomas. Hum Pathol (1997) 0.90
Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas. Neuro Oncol (2004) 0.90
Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas. J Korean Med Sci (1999) 0.87
Loss of chromosomes 22 and 14 in the malignant progression of meningiomas. A comparative study of fluorescence in situ hybridization (FISH) and standard cytogenetic analysis. Cancer Genet Cytogenet (1995) 0.85
Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. J Neurooncol (2007) 0.83
Correlation between cytogenetic and histopathological findings in 65 human meningiomas. Cancer Genet Cytogenet (1990) 0.77
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res (2006) 6.91
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res (2007) 4.99
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med (2013) 4.74
Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron (2007) 4.47
Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol (2004) 3.74
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
A multigene predictor of outcome in glioblastoma. Neuro Oncol (2009) 3.57
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet (2013) 3.19
Activation of p53 by MEG3 non-coding RNA. J Biol Chem (2007) 3.07
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab (2003) 2.68
The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol (2004) 2.66
MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol (2012) 2.41
Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol (2002) 2.39
Increased bone marrow fat in anorexia nervosa. J Clin Endocrinol Metab (2009) 2.31
Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations. Arch Pathol Lab Med (2009) 2.30
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol (2011) 2.27
MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res (2009) 2.11
Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol (2003) 2.08
Uncoupling of cardiovascular risk markers in adolescent girls with anorexia nervosa. J Pediatr (2006) 2.06
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One (2011) 2.04
Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab (2005) 2.03
Case records of the Massachusetts General Hospital. Case 8-2014. A 29-year-old man with headache, vomiting, and diplopia. N Engl J Med (2014) 2.01
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol (2010) 1.98
Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women. Obesity (Silver Spring) (2010) 1.93
Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients. IUBMB Life (2007) 1.92
Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab (2004) 1.81
Spindle cell oncocytoma of the adenohypophysis: report of two cases. Acta Neuropathol (2005) 1.81
Visceral fat is a negative predictor of bone density measures in obese adolescent girls. J Clin Endocrinol Metab (2010) 1.80
Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol (2011) 1.80
Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology (2009) 1.78
Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab (2011) 1.74
Effects of anorexia nervosa on clinical, hematologic, biochemical, and bone density parameters in community-dwelling adolescent girls. Pediatrics (2004) 1.73
Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol (2006) 1.70
Medical findings in outpatients with anorexia nervosa. Arch Intern Med (2005) 1.69
Fear conditioning and extinction: influence of sex and menstrual cycle in healthy humans. Behav Neurosci (2006) 1.68
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol (2012) 1.65
Fracture risk and areal bone mineral density in adolescent females with anorexia nervosa. Int J Eat Disord (2014) 1.64
Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med (2009) 1.63
A pseudolikelihood approach for simultaneous analysis of array comparative genomic hybridizations. Biostatistics (2006) 1.62
Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol (2002) 1.61
Marrow fat and bone--new perspectives. J Clin Endocrinol Metab (2013) 1.60
Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab (2002) 1.58
FGF21 and the late adaptive response to starvation in humans. J Clin Invest (2015) 1.55
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer Res (2003) 1.53
Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci U S A (2008) 1.52
Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res (2005) 1.52
Estradiol modulates medial prefrontal cortex and amygdala activity during fear extinction in women and female rats. Biol Psychiatry (2011) 1.51
Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro. Sci China Life Sci (2014) 1.51
Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J Clin Endocrinol Metab (2003) 1.49
Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab (2002) 1.48
CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer (2004) 1.48
Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell (2002) 1.48
Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene (2002) 1.45
Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab (2003) 1.44
Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab (2005) 1.43
AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res (2006) 1.41
Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls. Am J Physiol Endocrinol Metab (2008) 1.41
Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res (2006) 1.40
Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev (2007) 1.38
"Next-generation" pathology and laboratory medicine. Arch Pathol Lab Med (2011) 1.38
Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol (2007) 1.36
Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci (2008) 1.36
An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep (2013) 1.35
Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol (2002) 1.35
Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropathol Exp Neurol (2005) 1.34
The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer (2005) 1.34
Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J Clin Endocrinol Metab (2005) 1.34
Secretory dynamics of leptin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab (2005) 1.33
Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab (2008) 1.33
Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res (2004) 1.31
Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. Am J Pathol (2004) 1.30
Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab (2002) 1.29
BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res (2003) 1.29
Activation of paternally expressed genes and perinatal death caused by deletion of the Gtl2 gene. Development (2010) 1.28